Guided Therapeutics (GTHP) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Guided Therapeutics (GTHP) over the last 11 years, with Q3 2025 value amounting to -$0.01.
- Guided Therapeutics' EPS (Weighted Average and Diluted) changed 0.0% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.05, marking a year-over-year decrease of 6666.67%. This contributed to the annual value of -$0.05 for FY2024, which is 3853.48% up from last year.
- According to the latest figures from Q3 2025, Guided Therapeutics' EPS (Weighted Average and Diluted) is -$0.01, which was down 0.0% from -$0.01 recorded in Q2 2025.
- Guided Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.0 during Q3 2021, with a 5-year trough of -$0.09 in Q2 2021.
- In the last 5 years, Guided Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.01 in 2024 and averaged -$0.03.
- Per our database at Business Quant, Guided Therapeutics' EPS (Weighted Average and Diluted) soared by 8421.05% in 2021 and then plummeted by 68923.53% in 2022.
- Over the past 5 years, Guided Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.04 in 2021, then crashed by 50.14% to -$0.06 in 2022, then surged by 83.94% to -$0.01 in 2023, then tumbled by 33.09% to -$0.01 in 2024, then rose by 18.09% to -$0.01 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.01 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.01 in Q1 2025.